S
Sera Economics
← US Companies

Merck & Co., Inc.

MRK · NYSE · CIK 0000310158

SIC 2834

Pharmaceutical Preparations

Category

Chemicals

Entity

operating

Incorp.

NJ

Fiscal Y/E

1231

Source: SEC EDGAR · All filings on SEC →

Investment Indicators

$111.29

-0.09 (-0.08%)

Open

$112.15

High

$113.68

Low

$111.01

Prev Close

$111.38

Volume

6,126,862

52W High

$124.22

52W Low

$70.74

50-day MA

$117.35

Quote as of: 2026-05-11

Market Cap

$279.46B

P/E

31.87

P/B

5.31

PEG

3.46

EPS

3.55

BPS

21.26

Dividend Yield

2.90%

Beta

0.20

ROE

34.70%

ROA

13.34%

Current Ratio

1.54

Net Margin

28.08%

Intrinsic Value Estimates

Multiple valuation methods, each with its own assumptions — outputs can diverge widely

Median consensus (7 methods)

$273.81B

Fair +2.1%
MethodImplied market capvs current

Graham Number

√(22.5 × 순이익 × 자본)

$146.99B+90%

Graham Formula

순이익 × (8.5 + 2 × 성장률%)

$397.66B-30%

Justified P/E

순이익 × 산업 평균 P/E

$273.81B+2%

P/B 배수

자본 × 산업 평균 P/B

$78.91B+254%

P/S 배수

매출 × 산업 평균 P/S

$130.02B+115%

DCF (Gordon)

CF × (1+g) / (r − g)

$436.72B-36%

DDM (Gordon)

D × (1+g) / (r − g)

$288.89B-3%
▶ Detailed analysis — formula walk-through & scenarios

Why this conclusion

Of the 7 valuation methods, 7 were applicable. Their median fair-value lands +2.1% below the current market cap → the stock trades above most formulas' estimates (overvalued). 3 methods flag overvalued, 2 flag undervalued, the rest land within fair range. Read each formula's assumptions below before treating any single number as the answer.

Graham Number

Overvalued +90.1%

√(22.5 × 순이익 × 자본)

Current

$279.46B

Implied fair

$146.99B

Gap (current − fair)

+$132.47B(+90.1%)

NetIncome = $18.25B
Equity = $52.61B
√(22.5 × $18.25B × $52.61B) = $146.99B
  • 최대 PER 15배
  • 최대 PBR 1.5배
  • 안정적 흑자 기업 가정 (금융·고성장 부정확)

Graham Formula

Undervalued -29.7%

순이익 × (8.5 + 2 × 성장률%)

Current

$279.46B

Implied fair

$397.66B

Gap (current − fair)

$-118.20B(-29.7%)

NetIncome = $18.25B
Growth g = 6.6% → cap 6.6%
Multiple = 8.5 + 2 × 6.6 = 21.8×
$18.25B × 21.8 = $397.66B
  • EPS 성장률 6.6%/년 가정 (직전 1년 기준)
  • 무성장 기업 P/E = 8.5
  • 현재 적용 배수: 21.8x

Justified P/E

Fair +2.1%

순이익 × 산업 평균 P/E

Current

$279.46B

Implied fair

$273.81B

Gap (current − fair)

+$5.65B(+2.1%)

NetIncome = $18.25B
Industry P/E = 15×
$18.25B × 15 = $273.81B
  • 산업 평균 PER 15x 가정 (사용자 정의 가능)
  • 동종 업종 비교가 핵심 — 산업별 평균 P/E 사용 권장

P/B 배수

Overvalued +254.2%

자본 × 산업 평균 P/B

Current

$279.46B

Implied fair

$78.91B

Gap (current − fair)

+$200.55B(+254.2%)

Equity = $52.61B
Industry P/B = 1.5×
$52.61B × 1.5 = $78.91B
  • 산업 평균 PBR 1.5x 가정
  • 은행·보험·자산집약적 산업에 특히 유효

P/S 배수

Overvalued +114.9%

매출 × 산업 평균 P/S

Current

$279.46B

Implied fair

$130.02B

Gap (current − fair)

+$149.44B(+114.9%)

Revenue = $65.01B
Industry P/S = 2×
$65.01B × 2 = $130.02B
  • 산업 평균 PSR 2x 가정
  • 매출 기반 — 적자 기업·신생 기업에 적용 가능
  • 이익률 차이 무시

DCF (Gordon)

Undervalued -36.0%

CF × (1+g) / (r − g)

Current

$279.46B

Implied fair

$436.72B

Gap (current − fair)

$-157.26B(-36.0%)

FCF = $12.36B
Discount r = 4.0% + 5.0% = 9.0%
Growth g = 6.0%
$12.36B × (1 + 6.0%) / (9.0% − 6.0%) = $436.72B
  • 현금흐름 입력: FCF (잉여현금흐름)
  • 할인율 9.0% (무위험 4.0% + 주식위험프리미엄 5.0%)
  • 영구 성장률 6.0% (실질 GDP 수준)

DDM (Gordon)

Fair -3.3%

D × (1+g) / (r − g)

Current

$279.46B

Implied fair

$288.89B

Gap (current − fair)

$-9.42B(-3.3%)

Dividend D = $8.18B
Discount r = 9.0%
Growth g = 6.0%
$8.18B × (1 + 6.0%) / (9.0% − 6.0%) = $288.89B
  • 배당 입력: 실제 지급 배당
  • 할인율 9.0%
  • 배당 영구 성장률 6.0%

DCF sensitivity: discount rate × terminal growth

Each cell is the (current vs FCF × (1+g) / (r − g)) discount % under the assumed growth g and discount r.

g \ r7%8%9%10%11%
1%+34.3%+56.7%+79.1%+101.5%+123.9%
2%+10.8%+33.0%+55.2%+77.3%+99.5%
3%-12.2%+9.8%+31.7%+53.7%+75.6%
4%-34.8%-13.0%+8.7%+30.4%+52.2%
5%-56.9%-35.4%-13.9%+7.7%+29.2%

DDM sensitivity: discount rate × dividend growth

Each cell is the discount % vs Dividend × (1+g) / (r − g) under the assumed growth g and discount r.

g \ r7%8%9%10%11%
1%+103.1%+136.9%+170.7%+204.6%+238.4%
2%+67.6%+101.1%+134.6%+168.1%+201.6%
3%+32.7%+65.9%+99.1%+132.3%+165.5%
4%-1.4%+31.5%+64.3%+97.2%+130.1%
5%-34.9%-2.3%+30.2%+62.8%+95.3%

All estimates rest on strong assumptions. Treat the spread, not any single number, as the signal.

Financial Statements

In USD millions (per-share figures shown directly) · Financials as of: 2026-02-24

Income Statement

FY20252024202320222021
Revenue65,01164,16860,11559,28348,704
Cost of Revenue16,38215,19316,12617,41113,626
Net Income18,25417,11736514,51913,049
EPS (Basic)7.306.760.145.735.16
EPS (Diluted)7.286.740.145.715.14

Balance Sheet

FY20252024202320222021
Total Assets136,866117,106106,675109,160105,694
Current Assets43,51638,78232,16835,72230,266
Cash & Equivalents14,56513,2426,84112,6948,096
Current Liabilities28,32728,42025,69424,23923,872
Total Equity52,60646,31337,58145,99138,184

Cash Flow

FY20252024202320222021
Operating CF16,47221,468
Investing CF-13,741-7,734
Financing CF-1,922-7,032
CapEx4,1123,3723,863
Dividends Paid8,1767,8407,4457,0126,610

📄 SEC Filings

Other filings (90)
4

Insider Transaction

PRIMARY DOCUMENT

2026-05-07

Open →

4

Insider Transaction

PRIMARY DOCUMENT

2026-05-07

Open →

4

Insider Transaction

PRIMARY DOCUMENT

2026-05-07

Open →

4

Insider Transaction

PRIMARY DOCUMENT

2026-05-07

Open →

4

Insider Transaction

PRIMARY DOCUMENT

2026-05-07

Open →

4

Insider Transaction

PRIMARY DOCUMENT

2026-05-07

Open →

4

Insider Transaction

PRIMARY DOCUMENT

2026-05-07

Open →

4

Insider Transaction

PRIMARY DOCUMENT

2026-05-07

Open →

4

Insider Transaction

PRIMARY DOCUMENT

2026-05-07

Open →

4

Insider Transaction

PRIMARY DOCUMENT

2026-05-07

Open →

4

Insider Transaction

PRIMARY DOCUMENT

2026-05-07

Open →

4

Insider Transaction

PRIMARY DOCUMENT

2026-05-07

Open →

4

Insider Transaction

PRIMARY DOCUMENT

2026-05-05

Open →

4

Insider Transaction

PRIMARY DOCUMENT

2026-05-05

Open →

3/A

3/A

PRIMARY DOCUMENT

2026-05-05

Open →

SC TO-T/A

SC TO-T/A

SC TO-T/A

2026-05-05

Open →

3

3

PRIMARY DOCUMENT

2026-05-04

Open →

4

Insider Transaction

PRIMARY DOCUMENT

2026-05-01

Open →

4

Insider Transaction

PRIMARY DOCUMENT

2026-05-01

Open →

4

Insider Transaction

PRIMARY DOCUMENT

2026-05-01

Open →

4

Insider Transaction

PRIMARY DOCUMENT

2026-05-01

Open →

4

Insider Transaction

PRIMARY DOCUMENT

2026-05-01

Open →

4

Insider Transaction

PRIMARY DOCUMENT

2026-05-01

Open →

4

Insider Transaction

PRIMARY DOCUMENT

2026-05-01

Open →

4

Insider Transaction

PRIMARY DOCUMENT

2026-05-01

Open →

4

Insider Transaction

PRIMARY DOCUMENT

2026-05-01

Open →

4

Insider Transaction

PRIMARY DOCUMENT

2026-05-01

Open →

4

Insider Transaction

PRIMARY DOCUMENT

2026-05-01

Open →

SCHEDULE 13G

SCHEDULE 13G

xslSCHEDULE_13G_X02/primary_doc.xml

2026-04-30

Open →

SC TO-T/A

SC TO-T/A

SC TO-T/A

2026-04-24

Open →

ARS

ARS

ARS

2026-04-08

Open →

DEFA14A

DEFA14A

DEFA14A

2026-04-08

Open →

SC TO-T

SC TO-T

SC TO-T

2026-04-07

Open →

4

Insider Transaction

PRIMARY DOCUMENT

2026-04-01

Open →

4

Insider Transaction

PRIMARY DOCUMENT

2026-04-01

Open →

4

Insider Transaction

PRIMARY DOCUMENT

2026-04-01

Open →

SCHEDULE 13G/A

SCHEDULE 13G/A

xslSCHEDULE_13G_X02/primary_doc.xml

2026-03-27

Open →

3

3

PRIMARY DOCUMENT

2026-03-12

Open →

144/A

144/A

xsl144X01/primary_doc.xml

2026-02-13

Open →

4

Insider Transaction

PRIMARY DOCUMENT

2026-02-12

Open →

144

144

xsl144X01/primary_doc.xml

2026-02-10

Open →

4

Insider Transaction

PRIMARY DOCUMENT

2026-02-10

Open →

144

144

xsl144X01/primary_doc.xml

2026-02-09

Open →

144

144

xsl144X01/primary_doc.xml

2026-02-09

Open →

4

Insider Transaction

PRIMARY DOCUMENT

2026-02-09

Open →

4

Insider Transaction

PRIMARY DOCUMENT

2026-02-09

Open →

144

144

xsl144X01/primary_doc.xml

2026-02-06

Open →

144

144

xsl144X01/primary_doc.xml

2026-02-06

Open →

4

Insider Transaction

PRIMARY DOCUMENT

2026-02-06

Open →

144

144

xsl144X01/primary_doc.xml

2026-02-06

Open →

4

Insider Transaction

PRIMARY DOCUMENT

2026-02-06

Open →

4

Insider Transaction

PRIMARY DOCUMENT

2026-02-06

Open →

4

Insider Transaction

PRIMARY DOCUMENT

2026-02-06

Open →

4

Insider Transaction

PRIMARY DOCUMENT

2026-02-06

Open →

4

Insider Transaction

PRIMARY DOCUMENT

2026-02-06

Open →

4

Insider Transaction

PRIMARY DOCUMENT

2026-02-06

Open →

4

Insider Transaction

PRIMARY DOCUMENT

2026-02-06

Open →

144

144

xsl144X01/primary_doc.xml

2026-02-05

Open →

144

144

xsl144X01/primary_doc.xml

2026-02-04

Open →

144

144

xsl144X01/primary_doc.xml

2026-02-04

Open →

144

144

xsl144X01/primary_doc.xml

2026-02-04

Open →

144

144

xsl144X01/primary_doc.xml

2026-02-04

Open →

4

Insider Transaction

PRIMARY DOCUMENT

2026-01-28

Open →

4

Insider Transaction

PRIMARY DOCUMENT

2026-01-28

Open →

4

Insider Transaction

PRIMARY DOCUMENT

2026-01-28

Open →

4

Insider Transaction

PRIMARY DOCUMENT

2026-01-28

Open →

4

Insider Transaction

PRIMARY DOCUMENT

2026-01-28

Open →

4

Insider Transaction

PRIMARY DOCUMENT

2026-01-28

Open →

4

Insider Transaction

PRIMARY DOCUMENT

2026-01-28

Open →

4

Insider Transaction

PRIMARY DOCUMENT

2026-01-28

Open →

4

Insider Transaction

PRIMARY DOCUMENT

2026-01-28

Open →

4

Insider Transaction

PRIMARY DOCUMENT

2026-01-28

Open →

4

Insider Transaction

PRIMARY DOCUMENT

2026-01-28

Open →

SC TO-T/A

SC TO-T/A

SC TO-T/A

2026-01-07

Open →

4

Insider Transaction

PRIMARY DOCUMENT

2026-01-05

Open →

4

Insider Transaction

PRIMARY DOCUMENT

2026-01-05

Open →

4

Insider Transaction

PRIMARY DOCUMENT

2026-01-05

Open →

SC TO-T/A

SC TO-T/A

SC TO-T/A

2025-12-19

Open →

SC TO-T/A

SC TO-T/A

SC TO-T/A

2025-12-17

Open →

SC TO-T

SC TO-T

SC TO-T

2025-12-05

Open →

424B5

424B5

424B5

2025-12-03

Open →

FWP

FWP

FWP

2025-12-02

Open →

424B5

424B5

424B5

2025-12-01

Open →

4

Insider Transaction

PRIMARY DOCUMENT

2025-11-12

Open →

144

144

xsl144X01/primary_doc.xml

2025-11-10

Open →

4

Insider Transaction

PRIMARY DOCUMENT

2025-11-04

Open →

144

144

xsl144X01/primary_doc.xml

2025-11-03

Open →

4

Insider Transaction

PRIMARY DOCUMENT

2025-10-02

Open →

4

Insider Transaction

PRIMARY DOCUMENT

2025-10-02

Open →

4

Insider Transaction

PRIMARY DOCUMENT

2025-10-02

Open →

Merck & Co., Inc. (MRK) — Pharmaceutical Preparations | Sera Economics